Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Changes in Stockholders??? Equity (Deficit)

v3.25.1
Consolidated Statements of Changes in Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock [Member]
Treasury Stock, Common [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Other Comprehensive Loss [Member]
Beginning balance, value at Dec. 31, 2022 $ 24,881 $ 275,572 $ (250,219) $ (472)
Beginning balance, shares at Dec. 31, 2022   2,063,074        
Beginning balance, treasury stock, shares at Dec. 31, 2022          
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options, net of vesting of restricted shares 58 58
Exercise of stock options, net of vesting of restricted shares, shares   1,895        
Release of restricted stock
Release of restricted stock, shares   99,901        
Issuance of common stock under the 2018 employee stock purchase plan 48 48
Issuance of common stock under the 2018 employee stock purchase plan, shares   2,019        
Issuance of common stock in lieu of cash bonus and consulting fees 434 434
Issuance of common stock in lieu of cash bonus and consulting fees, shares   20,089        
Common stock issued upon conversion of 2022 Promissory Note 1,800 1,800
Common stock issued upon conversion of 2022 Promissory Note, shares   208,453        
Sales of common stock, net of issuance costs 10,476 10,476
Sales of common stock, net of issuance costs, shares   1,466,147        
Stock-based compensation expense 4,079   4,079
Cumulative translation adjustment 54 54
Treasury stock repurchase $ (502)   $ (502)
Treasury stock repurchase, shares 10,130   (10,130)      
Net Income (Loss) $ (52,785) (52,785)
Ending balance, value at Dec. 31, 2023 $ (11,457) $ (502) 292,467 (303,004) (418)
Ending balance, shares at Dec. 31, 2023 3,851,448 3,861,578        
Ending balance, treasury stock, shares at Dec. 31, 2023     (10,130)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Release of restricted stock
Release of restricted stock, shares   119,765        
Issuance of common stock in lieu of cash bonus and consulting fees 35 35
Issuance of common stock in lieu of cash bonus and consulting fees, shares   11,453        
Common stock issued upon conversion of 2022 Promissory Note 4,505 4,505
Common stock issued upon conversion of 2022 Promissory Note, shares   336,550        
Sales of common stock, net of issuance costs 122,342 $ 2 122,340
Sales of common stock, net of issuance costs, shares   15,695,688        
Fractional share issuances as a result of reverse stock split
Fractional share issuances as a result of reverse stock split, shares   141,631        
Stock-based compensation expense 1,656 1,656
Cumulative translation adjustment          
Loss on disposal of subsidiaries 418   418
Net Income (Loss) (10,316) (10,316)
Ending balance, value at Dec. 31, 2024 $ 107,183 $ 2 $ (502) $ 421,003 $ (313,320)
Ending balance, shares at Dec. 31, 2024 20,156,535 20,166,665        
Ending balance, treasury stock, shares at Dec. 31, 2024     (10,130)